SENTI-202-101 Promising Results in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Ongoing Phase 1 Trial (SENTI-202-101) December 9, 2025 Conference Call and Webcast NASDAQ: SNTI | sentibio.com Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our") within the meaning of the Private Securities Litigation Reform Act of 1995. Statements we make in this presentation may include statements which are not historical f ...

Trademarks and Trade Names This Presentation contains trademarks, service marks and trade names of third parties, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this Presentation is not intended to, and does not imply, a relationship with THIL, or an endorsement or sponsorship by or of THIL. Solely for convenience, the trademarks, service marks and trade names referred to in this Presentation may appear without th ...

Company Strategy and Outlook - Klabin reaffirms its commitment to developing its people for future challenges and ensuring management continuity with a culture of excellence[10] - The company emphasizes strategic planning and financial discipline as drivers for capital allocation, aiming to maximize shareholder value generation[27, 29] - Klabin is focused on extending debt maturities and reducing debt, reinforcing its deleveraging trajectory[32] Financial Performance and Discipline - Klabin maintains its 2025 guidance, reflecting its ability to adapt and capture efficiencies[41] - The company projects total cash cost to be less than R$3300 per ton in 2026, assuming an accumulated IPCA of 14% which would be R$3600 per ton[38, 39] - Klabin anticipates CAPEX between R$2 billion and R$25 billion for 2026[45] Shareholder Returns - Klabin declared interim dividends of R$11 billion based on accumulated profits recorded in 2025[47] - The company is increasing capital with bonus shares, representing 1% of the current share base[50] - Klabin paid R$13 billion in dividends in LTM3Q25, representing a 55% dividend yield[32] Competitive Advantages - Klabin has a unique forest asset base, providing privileged access to long fiber and high forest productivity[17, 19] - The company has a diversified business model with leadership positions in niche markets, including a 22% market share in corrugated boxes and a 50% market share in industrial bags in Brazil[20, 24]

Financial Performance and Outlook - CVS Health aims for mid-teens adjusted EPS CAGR through 2028, driven by diversified businesses[14, 15, 162] - The company expects at least $400 billion in total revenues for 2026[152] - The adjusted operating income for 2026 is projected to be between $1507 billion and $1541 billion[152] - Adjusted earnings per share are guided to be between $700 and $720 for 2026[152] - CVS Health anticipates at least $10 billion in cash flow from operations in 2026[152] Business Segment Performance - Health Care Benefits expects at least $137 billion in revenue for 2026, with a year-over-year decline of (35)%, and adjusted operating income between $358 billion and $392 billion[148] - Health Services projects at least $1966 billion in revenue for 2026, with a year-over-year growth of +3%, and adjusted operating income of at least $725 billion[149] - Pharmacy and Consumer Wellness anticipates at least $1365 billion in revenue for 2026, with a year-over-year decline of (15)%, and adjusted operating income of at least $609 billion[150, 151] Strategic Initiatives - CVS Health is launching "Engagement as a Service" built around the Open Consumer Engagement Platform, with an open platform launch goal in 2026[133] - The company projects cumulative deployable cash of $55 to $60 billion from 2026 to 2028, allocating approximately 60% to shareholder dividends and 40% to flexible deployment[161]

Earnings Presentation Q1 Fiscal 2026 1 Rebecca Gardy Chief Investor Relations Officer Welcome Today's Agenda Mick Beekhuizen Chief Executive Officer Business Update Todd Cunfer Chief Financial Officer Financial Results and Outlook 2 Forward-looking Statements Safe Harbor Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements reflect our current expectations regarding our future results o ...

Fiscal 2025 Third Quarter Results December 9, 2025 CAUTIONARY STATEMENTS Cautionary Note Regarding Forward-Looking Statements This presentation and accompanying discussion may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, all statements other than statements of historical or current facts relating to our intentions, beliefs, assumptions or current expectations concerning, among other th ...

SAFETY is a non-negotiable value for Vibra Transportation accidents 0,12 0,07 0,05 0,06 0,05 0,07 0,04 0,03 0,02 0,03 0,02 Reviewing VIBRA's Golden Rules Closer focus on critical activities Transport Accident Frequency Rate (TFAT) Process Safety Vibra focused its efforts on implementing a risk-based Process Safety program. The program's main goal is to enhance the company's ability to identify, assess and control the risks inherent in its operations, reducing employees' exposure to accidents, especially hig ...

© Cullinan Therapeutics, Inc. All rights reserved. Confidential and proprietary. | 2 Agenda Introduction & Pipeline Strategy Nadim Ahmed CLN-049 Update at ASH December 8, 2025 Important notice and disclaimers This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including express or implied statements regarding the Company's beliefs and expectat ...

Core Portfolio & Strategy - Park Hotels & Resorts focuses on upper-upscale and luxury full-service hotels in premier urban and resort destinations, affiliated with dominant global brands[4] - The company's core portfolio includes 20 consolidated hotels and 1 unconsolidated hotel, totaling 16,000 rooms[13] - Park plans to dispose of non-core hotels to enhance growth and quality, with estimated proceeds of $560 million to $600 million expected from non-core hotel sales[55, 61] - The strategic plan involves disposing of remaining non-core hotels over the next 12+ months to materially enhance growth and quality[46] Financial Performance & Valuation - Park Hotels & Resorts is trading at a 47% discount to the consensus estimate of NAV (Net Asset Value)[14] - The implied market value of the portfolio is $270,000 per key, while the replacement cost for the core portfolio is approximately $1 million per key[14] - The company offers an attractive dividend yield of 9%[14] - The company has over $2 billion of liquidity, including $1 billion available under the revolving credit facility and an unsecured $800 million delayed-draw term loan[15] ROI & Growth Potential - Park Hotels & Resorts has a robust ROI pipeline with $1 billion of potential opportunities, with past projects generating 20%+ average IRR (Internal Rate of Return)[15] - Since 2018, $1.4 billion of capital will have been invested in the core portfolio through 2025, or $87,000 per key[14] - The company anticipates $100 million+ Adjusted EBITDA growth potential as core markets recover and ROI projects stabilize[14]

Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 in Recurrent Genital Herpes December 8, 2025 Nasdaq: ASMB ©2025 ASSEMBLY BIOSCIENCES, INC. Cautionary Note Regarding Forward-Looking Statements The information in this presentation contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio's ability to re ...